Citation Impact
Citing Papers
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
2011 Standout
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
2008
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
2008 Standout
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
2010
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Alteration of enzyme specificity by computational loop remodeling and design
2009 StandoutNobel
Treatment of Steroid-Resistant Acute Graft-Versus-Host Disease with Rabbit Antithymocyte Globulin
2000
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2007 Standout
Treatment Decisions After Diagnosis of Metastatic Colorectal Cancer
2011
Pancreatic cancer
2004 Standout
Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients
2004
Contribution of platelets to tumour metastasis
2011 Standout
Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study
2011
Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment
2010
Treatment of severe acute graft‐versus‐host disease with anti‐thymocyte globulin
2001
Acute graft-vs-host disease
2001
Pyoderma gangrenosum: Classification and management
1996 Standout
Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft‐versus‐leukaemia effect
1988
An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors
2003
Cytolytic pathways in haematopoietic stem-cell transplantation
2002
Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.
1994
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
2012
Nasopharyngeal carcinoma
2019 Standout
ACUTE BLEEDING AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION: ASSOCIATION WITH GRAFT VERSUS HOST DISEASE AND EFFECT ON SURVIVAL1
1999
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
1996 Standout
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
2011
Colorectal cancer
2013 Standout
Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer
2002
Graft-versus-host disease and the Th1/Th2 paradigm
1996
Dendritic Cell Function in Vivo during the Steady State: A Role in Peripheral Tolerance
2003 StandoutNobel
FK317: a novel substituted dihydrobenzoxazine with potent antitumor activity which does not induce vascular leak syndrome
1998
An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer
2011
Colorectal cancer
2019 Standout
Noncovalent drug-DNA binding interactions that inhibit and stimulate (A)BC excinuclease
1991 StandoutNobel
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
2004 Standout
Signalling pathways of the TNF superfamily: a double-edged sword
2003 Standout
Tumor necrosis factor inhibitor ameliorates murine intestinal graft-versus-host disease
1999 StandoutNobel
Outcomes among 562 Recipients of Placental-Blood Transplants from Unrelated Donors
1998 Standout
Adjuvant Therapy of Stage II and III Colon Cancer
2005
A Ribosomopathy Reveals Decoding Defective Ribosomes Driving Human Dysmorphism
2017 StandoutNobel
Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma?
1989
Graft-versus-host disease
2009 Standout
Intestinal mucosal barrier function in health and disease
2009 Standout
A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
1997 StandoutNature
Adjuvant Therapy for Colon Cancer 2005: New Options in the Twenty-First Century
2006
Can graft-versus-leukemia reactivity be dissociated from graft-versus-host disease?
2007
Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy
2011
Pathophysiology of Graft-Versus-Host Disease
2006
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study
2008 Standout
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
2012 Standout
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer
2007 Standout
TNF-α targeted therapeutic approaches in patients with hematologic malignancies
2002
Analysis of 462 Transplantations from Unrelated Donors Facilitated by the National Marrow Donor Program
1993
Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference
2008
Identification of Clonogenic Common Lymphoid Progenitors in Mouse Bone Marrow
1997 Standout
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
2013 Standout
Pancreatic Cancer
2010 Standout
Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial
2011
Monoclonal antibodies for the prevention and treatment of graft-versus-host disease
2003
Role of interleukin 10 in specific immunotherapy.
1998 Standout
Prognostic significance of increased IL-10 production in patients prior to allogeneic bone marrow transplantation
2000
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Clinical Management of Oxaliplatin-Associated Neurotoxicity
2005
Hepatocellular carcinoma pathogenesis: from genes to environment
2006 Standout
Treatment of Multiple Myeloma: A Comprehensive Review
2009
The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen
2011
Pancreatic cancer and thromboembolic disease
2004
High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer
1990
Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study
2010
Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation
2000
Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer
2011
Pancreatic cancer
2011 Standout
Cancer of the Ovary
2004 Standout
How I treat refractory acute GVHD
2007
Gemcitabine Combined With Oxaliplatin in Advanced Pancreatic Adenocarcinoma: Final Results of a GERCOR Multicenter Phase II Study
2002
In vivoTherapeutic Responses Contingent on Fanconi Anemia/BRCA2 Status of the Tumor
2005
Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease
1994
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia [see comments]
1995 Standout
Human mesenchymal stem cells modulate allogeneic immune cell responses
2004 Standout
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
2009 Standout
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
2006 Standout
Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
2005 Standout
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Nonintercalating DNA-binding ligands: Specificity of the interaction and their use as tools in biophysical, biochemical and biological investigations of the genetic material
1986
XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer
2004
TNF-TNFR2 Interactions Are Critical for the Development of Intestinal Graft-Versus-Host Disease in MHC Class II-Disparate (C57BL/6J→C57BL/6J × bm12)F1 Mice
2002
Capecitabine Plus Erlotinib in Gemcitabine-Refractory Advanced Pancreatic Cancer
2007
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
Oral Glutamine Is Effective for Preventing Oxaliplatin-Induced Neuropathy in Colorectal Cancer Patients
2007
Recipient Tumor Necrosis Factor- and Interleukin-10 Gene Polymorphisms Associate With Early Mortality and Acute Graft-Versus-Host Disease Severity in HLA-Matched Sibling Bone Marrow Transplants
1999
High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells.
1994
Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials
2005
Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents
2008
T-cell depletion of HLA-identical transplants in leukemia
1991
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
2014 Standout
Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).
1997
Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
2006
Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3
2009
Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity
1994
Interleukin-10 and the Interleukin-10 Receptor
2001 Standout
Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial
2005
High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma
1987
Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect
2001
Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancer—A Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer Study
2005
Cytokine dysregulation and acute graft-versus-host disease
1992
Immunobiology of acute graft-versus-host disease.
1987
Interleukin-1 enhances survival of lethally irradiated mice treated with allogeneic bone marrow cells
1989
GITR Activation Induces an Opposite Effect on Alloreactive CD4+ and CD8+ T Cells in Graft-Versus-Host Disease
2004 StandoutNobel
The Role of B7 Costimulation in CD4/CD8 T Cell Homeostasis
2000 StandoutNobel
Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies
2007
Tolerogenic Dendritic Cells
2003 StandoutNobel
Multiple Myeloma
2011 Standout
A controlled trial of recombinant human granulocyte-macrophage colony- stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma
1992
World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997
1999 Standout
Interleukin-1 and interleukin-1 antagonism
1991 Standout
Phase III Study Comparing a Semimonthly With a Monthly Regimen of Fluorouracil and Leucovorin As Adjuvant Treatment for Stage II and III Colon Cancer Patients: Final Results of GERCOR C96.1
2007
Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)
2010
Metronomic chemotherapy and immunotherapy in cancer treatment
2017
Works of M. Flesch being referenced
Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study
2009
Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM)
2001
Randomized adjuvant study comparing two schemes of 5-fluorouracil and leucovorin in stage B2 and C colon adenocarcinoma: Study design and preliminary safety results
2001
Marrow transplantation from HLA non-identical family donors for the treatment of leukaemia: a pilot study of 15 patients using additional immunosuppression and T-cell depletion
1988
Pyoderma gangrenosum in an allogeneic bone marrow transplant recipient i
1989
Semimonthly Versus Monthly Regimen of Fluorouracil and Leucovorin Administered for 24 or 36 Weeks as Adjuvant Therapy in Stage II and III Colon Cancer: Results of a Randomized Trial
2003
Bone marrow transplantation in multiple myeloma: report from the European Cooperative Group for Bone Marrow Transplantation
1987
Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double- blind placebo-controlled trial
1992
Intensive cytoreductive regimen and autologous bone marrow transplantation in leukemia. Present status and the future. A review
1983
OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study
2006
Melphalan-Prednisone-Thalidomide (MP-T) Demonstrates a Significant Survival Advantage in Elderly Patients ≥75 Years with Multiple Myeloma Compared with Melphalan-Prednisone (MP) in a Randomized, Double-Blind, Placebo-Controlled Trial, IFM 01/01.
2007
High-risk pregnancies in Diamond-Blackfan anemia: a survey of 64 pregnancies from the French and German registries.
2006
Autologous bone marrow transplantation (ABMT) for acute leukaemia in complete remission: a pilot study of 33 cases
1986
Monoclonal anti TNF alpha antibody in the treatment of acute GvHD refractory both to corticosteroids and anti IL-2 R antibody.
1991
Successful graft-versus-host disease prevention without graft failure in 32 HLA-identical allogeneic bone marrow transplantations with marrow depleted of T cells by monoclonal antibodies and complement
1987
Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease
1992
OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer
2004
Autoimmune-like thrombocytopenia after bone marrow transplantation [letter; comment]
1989
OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer
2004
Autoimmune-like thrombocytopenia after bone marrow transplantation.
1989
Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease
1992
Reintroduction of Oxaliplatin Is Associated With Improved Survival in Advanced Colorectal Cancer
2007
Gemcitabine Combined With Oxaliplatin in Advanced Pancreatic Adenocarcinoma: Final Results of a GERCOR Multicenter Phase II Study
2002
Folfiri then folfox of folfox then folfiri in metastatic colorectal cancer (MCRC): results of a phase III trial
2001